HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.

Abstract
Multiple sclerosis (MS) is a severe debilitating disorder characterized by progressive demyelination and axonal damage of the central nervous system (CNS). Current therapies for MS inhibit the immune response and demonstrate reasonable benefits if applied during the early phase of relapsing–remitting MS (RRMS) while there are no treatments for patients that progress neither to the chronic phase nor for the primary progressive form of the disease. In this manuscript, we have studied the therapeutic efficacy of a cell and gene therapy strategy for the treatment of a mouse model of chronic MS [myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE)]. We used allogenic mesenchymal stem cells (MSCs) asa therapeutic tool and also as vehicle to deliver fully processed 3.3-kDa vasoactive intestinal peptide (VIP) to the peripheral immune organs and to the inflamed CNS. Intraperitoneal administrations of MSCs expressing VIP stopped progression and reduced symptoms when administered at peak of disease. The improvement in clinical score correlated with diminished peripheral T-cell responses against MOG as well as lower inflammation,lower demyelination, and higher neuronal integrity in the CNS. Interestingly, neither lentiviral vectors expressing VIP nor unmodified MSCs were therapeutic when administer at the peak of disease. The increased therapeutic effect of MSCs expressing VIP over unmodified MSCs requires the immunoregulatory and neuroprotective roles of both VIP and MSCs and the ability of the MSCs to migrate to peripheral lymph organs and the inflamed CNS.
AuthorsMarién Cobo, Per Anderson, Karim Benabdellah, Miguel G Toscano, Pilar Muñoz, Angélica García-Pérez, Iván Gutierrez, Mario Delgado, Francisco Martin
JournalCell transplantation (Cell Transplant) Vol. 22 Issue 5 Pg. 839-54 ( 2013) ISSN: 1555-3892 [Electronic] United States
PMID23031550 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Myelin-Oligodendrocyte Glycoprotein
  • Vasoactive Intestinal Peptide
Topics
  • Adipose Tissue (cytology)
  • Animals
  • Central Nervous System (metabolism)
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental (chemically induced, therapy)
  • Female
  • Forkhead Transcription Factors (metabolism)
  • Immunophenotyping
  • Inflammation (pathology)
  • Infusions, Parenteral
  • Lentivirus (genetics)
  • Male
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells (cytology, metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Myelin-Oligodendrocyte Glycoprotein (toxicity)
  • T-Lymphocytes (cytology, immunology)
  • Transplantation, Homologous
  • Vasoactive Intestinal Peptide (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: